CHRS
Coherus Oncology, Inc.
NASDAQ · Healthcare · Biotechnology · US
$1.35
+9.76%Price chart
Aug 19Aug 24Aug 27Sep 1Sep 4Sep 10Sep 15Sep 18
Key dataSep 18, 2026
Open$1.23
From 52W high−46.22%
Volume3.12M
Market cap$208.58M
P/E (TTM)—
P/S (TTM)4.1x
Div yield—
Key dataSep 18, 2026
Open
$1.23
From 52W high
−46.22%
Volume
3.12M
Market cap
$208.58M
ValuationView details →
P/E (Fwd)
—
EV/EBITDA
−0.9x
P/E (TTM)
—
RSI (14)
45.2
MomentumView details →
1D Return
+9.76%
YTD Return
−10.07%
SummaryUpdated Jun 1, 2026
Coherus BioSciences, Inc. (NASDAQ:CHRS) is a biopharmaceutical company founded in 2010 and headquartered in Redwood City, California. Originally established as BioGenerics, Inc., the company changed its name to Coherus BioSciences in April 2012 and went public in November 2014. The company has undergone a significant strategic transformation, evolving from a biosimilar-focused business to an innovative oncology company. Following the divestiture of its biosimilar assets in 2024-2025, Coherus now concentrates exclusively on developing and commercializing novel cancer treatments, particularly focusing on immuno-oncology therapies that target the tumor microenvironment.
Similar companies
Latest newsMore news →
Coherus Oncology announced a special dividend of contingent value rights (CVRs) to its stockholders, entitling them to net proceeds from the sale of its remaining legacy biosimilar assets.34d agoCoherus Oncology, Inc. entered into a new $55 million senior secured term loan facility with Innovatus Life Sciences Lending Fund I, LP, fully drawing the Tranche A amount on August 14, 2026, to repay its prior term loan and for working capital.35d ago